Современные возможности терапии тяжелых микозов у детей раннего возраста


Г.Н. Буслаева

Тяжелые грибковые поражения довольно часто встречаются у детей раннего возраста, особенно у недоношенных новорожденных. Их основным патогеном является Candida albicans. В настоящее время в арсенале врачей имеется несколько групп противогрибковых препаратов, но не все они могут использоваться при тяжелых микозах у детей. По этим показаниям в настоящее время используются амфотерицин В, включая его липидные формы, флуцитозин (в России практически не применяется), флуконазол и эхиноканоиды (каспофунгин). Рассматриваются фармакологические свойства этих противогрибковых препаратов, обсуждается их клиническая эффективность у детей раннего возраста. Приводятся собственные результаты автора в отношении лечения грибковых менингитов у детей первого года жизни и переноси

Литература






  1. Baley JE, Kliegman RM, Fanaroff AA. Disseminated fungal infections in very low-birth-weight infants: clinical manifesta-tions and epidemiology. Pediatrics 1984;73:144–52.


  2. Baley JE, Silverman A. Systemic candidiasis: cutaneous mani-festations in low birth-weight infants. Pediatrics 1988;82:211–15.


  3. Faix RG, Kovarik SM, Shaw TR, et al. Mucocutaneous and invasive candidiasis among very low birth weight (less than 1500 grams) infants in intensive care nurseries: a prospective study. Pediatrics 1989;83(1):101–17.


  4. Johnson DE, Thompson TR, Green TP, et al. Systemic candi-diasis in very low-birth-weight infants (less than 1500 grams). Pediatrics 1984;73(2): 138–43.


  5. Weitkamp JH, Poets CF, Sievers R, et al. Candida infection in very low birth-weight infants: outcome and nephrotoxicity of treatment with liposomal amphotericin B (AmBisome). Infection 1998;26:11–15.


  6. Edwards MS. Fungal and protozoal infections. In: Fanaroff AA, Martin RJ, editors. Neonatal-perinatal medicine: diseases of the fetus and Infant. St Louis (MO): Mosby-Year Book Inc., 2002, р. 745–51.


  7. Weese-Mayer DE, Fondriest DW, Brouillette RT, et al. Risk factors associated with candidemia in the neonatal intensive care unit: a case-control study. Pediatr Infect Dis J 1987;6:190–96.


  8. Rowen JL, Tate JM. Management of neonatal candidiasis: Neo-natal Candidiasis Study Group. Pediatr Infect Dis J 1998;17(11):1007–11.


  9. Stoll BJ, Gordon T, Korones SB, et al. Early-onset sepsis in very low birth weight neonates: a report from the National Institute of Child Health and Human Development Neonatal Research Network. J Pediatr 1996;129(1):72–80.


  10. Leibovitz E. Neonatal candidosis: clinical picture, management controversies and consensus, and new therapeutic options. J Antimicrob Chemother 2002;49(Suppl. 1):69–73.


  11. Saiman L, Ludington E, Dawson JD, et al. The National Epidemiology of Mycoses Study Group. Risk factors for Candida species colonization of neonatal intensive care unit patients. Pediatr Infect Dis J 2001;20(12):1119–24.


  12. Saiman L, Ludington E, Pfaller M, et al. Risk factors for candidemia in neonatal intensive care unit patients: the National Epidemiology of Mycosis Survey Study Group. Pediatr Infect Dis J 2000;19(4):319–24.


  13. Ng PC. Systemic fungal infections in neonates. Arch Dis Child 1994;71:F130–35.


  14. Evdoridou J, Roilides E, Bibashi E, et al. Multifocal osteoar-thritis due to Candida albicans in a neonatc: serum level monitoring of liposomal amphotericin B and literature review. Infection 1997;25(2):112–16.


  15. Anderson DC, Pickering LK, Feigin RD. Leukocyte function in normal and infected neonates. J Pediatr 1974;85(3):420–25.


  16. Shigeoka AO, Charette RP, Wyman ML, et al. Defective oxidative metabolic responses of neutrophils from stressed neonates. J Pediatr 1981; 98(3):392–98.


  17. Cairo MS. Neonatal neutrophil host defense: prospects for immunologic enhancement during neonatal sepsis. Am J Dis Child 1989;143(1):40–46.


  18. Baley JE, Kliegman RM, Boxerbaum B, et al. Fungal coloniza-tion in the very low birth weight infant. Pediatrics 1986;78:225–32.


  19. WelbelSF, McNeil MM, Kuykendall RJ, et al. Candida parap-silosis bloodstream infections in neonatal intensive care unit patients: epidemiologic and laboratory confirmation of a common source outbreak. Pediatr Infect Dis J 1996;15(11): 998–1002.


  20. Starke JR, Mason Jr EO, Kramer WG, et al. Pharmacokinetics of amphotericin B in infants and children. J Infect Dis 1987;155(4):766–74.


  21. Baley JE, Meyers C, Kliegman RM, et al. Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates. J Pediatr 1990;116(5):791–97.


  22. Boswell GW, Buell D, Bekersky I. AmBisome (liposomal amphotericin B): a comparative review. J Clin Pharmacol 1998;38(7):583–92.


  23. AmBisome. In: Physician's desk reference. 54th ed. Montvale (NJ): Medical Economics Co. Inc., 2000, р. 1090–92.


  24. Abelcet. In: Physician's desk reference. 54th ed. Montvale (NJ):Medical Economics Co. Inc., 2000, р. 1653–55.


  25. Harm IM, Prentice HG. Lipid-based amphotericin B: a review of the last 10 years of use. Int J Antimicrob Agents 2001;17(3):161–69.


  26. Hill HR, Mitchell TG, Matsen JM, et al. Recovery from disseminated candidiasis in a premature neonate. Pediatrics 1974;53(5):748–52.


  27. Wiest DB, Fowler SL, Garner SS, et al. Fluconazole in neonatal disseminated candidiasis [letter]. Arch Dis Child 1991;66(8):1002.


  28. Krzeska I, Yeats RA, Pfaff G. Single dose intravenous pharmacokinetics of fluconazole in infants. Drugs Exp Clin Res 1993;19(6):267–71.


  29. Sax6n H, Hoppu K, Pohjavuori M. Pharmacokinetics of fluconazole in very low birth weight infants during the first two weeks of life. Clin Pharmacol Ther 1993;54(3):269–77.


  30. Marr B, Gross S, Cunningham C, et al. Candida sepsis and meningitis in a very-low-birth-weight infant successfully treated with fluconazole and flucytosine. Clin Infect Dis 1994;19(4):795–96.


  31. Wong SF, Leung MP, Chan MY. Pharmacokinetics of fluconazole in children requiring peritoneal dialysis. Clin Ther 1997;19(5):1039–47.


  32. Wenzl TG, Schefels J, Homchen H, et al. Pharmacokinetics of oral fluconazole in premature infants. Eur J Pediatr 1998;157(8):661–62.


  33. Graybill JR. The echinocandins, first novel class of antifungals in two decades: will they live up to their promise? Int J Clin Pract 2001;55:633–38.


  34. Groll AH, Piscitelli SC, Walsh TJ. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol 1998;44:343–500.


  35. Stone J, Holland S, Li S, et al. Effect of hepatic insufficiency on the pharmacokinetics of caspofungin [abstract no. A-14]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy,2001, Chicago.


  36. Nelly M, Blumer J. Caspofungin pharmacokinetics in two pediatric liver transplant patients. Clin Ther Res 2003;64:127–36.


  37. Mukai T, Ohkuma T, Nakahara K, et al. Pharmacokinetics of FK463, a novel echinocandin analogue, in elderly and non-elderly subjects [abstract no. A-30]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, 2001 Dec 16–19; Chicago.


  38. Pfaller MA, Bale M, Buschelman B, et al. Quality control guidelines for National Committee for Clinical Laboratory Standards recommended broth macrodilution testing of amphotericin B, fluconazole, and flucytosinc. J Clin Microbiol 1995; 33(5):1104–07.


  39. Driessen M, Ellis J, Cooper P, et al. Fluconazole vs amphotericin B for the treatment of neonatal fungal septicemia: a prospective randomized trial. Pediatr Infect Dis J 1996;15:1107–12.


  40. Faix RG. Systemic Candida infections in infants in intensive care nurseries: high incidence of central nervous system in volvement. J Pediatr 1984;105:616–22.


  41. Smego R, Perfect J. Combined therapy with amphotericin B and 5-fluorocytosine for Candida meningitis. Rev Infect Dis 1984;6:791–801.


  42. Hall JE, Cox F, Karlson K, et al. Amphotericin B dosage for disseminated candidiasis in premature infants. J Perinatol 1987;7(3):194–98.


  43. Loke HL, Verber I, Szymonowicz W, et al. Systemic candidiasis and pneumonia in preterm infants. Aust Paediatr J 1988;24(2):138–42.


  44. Butler K, Rench M, Baker C. Amphotericin B as a single agent in the treatment of systemic candidiasis in neonates. Pediatr Infect Dis J 1990;9: 51–56.


  45. Leibovitz E, luster-Reicher A, Amitai M, et al. Systemic candidal infections associated with use of peripheral venous catheters in neonates: a 9-year experience. Clin Infect Dis 1992;14:485–91.


  46. Click C, Graves G, Feldman S. Neonatal fungemia and amphotericin B. South Med J 1993;86: 1368–71.


  47. Donowitz L, Hendley J. Short-course amphotericin B therapy for candidemia in pediatric patients. Pediatrics 1995;95:888–91.


  48. Fernandez M, Moylett EH, Noyola DE, et al. Candidal meningitis in neonates: a 10-year review. Clin Infect Dis 2000;31:458–63.


  49. Zenker PN, Rosenberg EM, Van Dyke RB, et al. Successful medical treatment of presumed Candida endocarditis in critically ill infarits. J Pediatr 1991;119(3):472–77.


  50. Sanchez PJ, Siegel JD, Fishbein J. Candida endocarditis: successful medical management in three preterm infants and review of the literature. Pediatr Infect Dis J 1991;10(3):239–43.


  51. Lilien LD, Ramamurthy RS, Pildes RS. Candida albicans men-ingitis in a premature neonate successfully treated with 5-fluorocytosine and amphotericin B: a case report and review of the literature. Pediatrics 1978;61(1):57–61.


  52. Dennis D, Miller MJ, Peterson CG. Candida septicemia. Surg Gynecol Obstet 1969;119:520–30.


  53. Kozinn PJ. Candida meningitis successfully treated with amphotericin B. N Engl J Med 1963;268:881–84.


  54. Klein JD, Yamachi T, Horlick SP. Neonatal candidiasis, menin gitis, and arthritis: observations and a review of the literature. J Pediatr 1972; 81(1):31–34.


  55. Adler S, Randall J, Plotkin SA. Candida! osteomyelitis and arthritis in a neonate. Am J Dis Child 1972;123(6):595–96.


  56. Mahboubi S, Kaufmann HJ. Schut L. Two instances of in flammatory aqueductal occlusion in prematures after neonatal candidal septicemia. Clin Pediatr (Phila) 1976;15(7):651–53.


  57. Ingomar CJ, Terslev E. Candida albicans meningitis hos en nyft: tilfaelde kompliceret med hydrocephalus. Ugeskr Laeger 1964:126:1110–12.


  58. Nezelof C, Sarrut S. Infections mortelles a Candida chez le nouveau-nd et le nourisson: six observations anatomohisto-logiques.


  59. Bayer AS, Edwards Jr JE, Seidel JS, et al. Candida meningitis:report of seven cases and review of the English literature. Medicine (Baltimore) 1976;55(6):477–86.


  60. Michelson PE, Rupp R, Efthimiadis B. Endogenous Candida endophthalmitis leading to bilateral corneal perforation. Am J Ophthalmol 1975;80(5):800–03.


  61. Pittard WB, Thullen JD, Fanaroff AA. Neonatal septic arthri-tis. J Pediatr 1976;88(4 Pt 1): 621–24.


  62. Adler-Shohet F, Waskin H, Lieberman JM. Amphotericin B lipid complex for neonatal invasive candidiasis. Arch Dis Child Fetal Neonatal Ed 2001;84(2):F131–33.


  63. Ldpez Sastre JB, Coto Cotallo CD, Fernandez Colomer B.Grupo de Hospitales Castrillo. Neonatal invasive candidiasis: a prospective multicenter study of 118 cases. Am J Perinatol 2003;20(3): 153–63.


  64. da Silva LP, Amaral JM, Ferreira NC. Which is the most appropriate dosage of liposomal Amphotericin-B (AmBisome) for the treatment of fungal infections in infants of very low birth weight? Pediatrics 1993;91(6):1217–18.


  65. Arishi H, Frayha HH, Kalloghlian A, et al. Liposomal amphotericin B in neonates with invasive candidiasis. Am J Perinatol 1997;14(9):573–76.


  66. Arishi H, Frayha HH, Kalloghlian A, et al. Liposomal amphotericin B in neonates with invasive candidiasis. Am J Perinatol 1998;15(11):643–48.


  67. Scarcella A, Pasquariello MB, Giugliano B, et al. Liposomal amphotericin B treatment for neonatal fungal infections. Pediatr Infect Dis J 1998;17(2):146–48.


  68. Juster-Reicher A, Leibovitz E, Linder N, et al. Liposomal amphotericin B (AmBisome) in the treatment of neonatal candidiasis in very low birth weight infants. Infection 2000;28(4):223–26.


  69. Wyble LE, Gal P, Ransom JL, et al. Fluconazole use and pharmacokinetics in three premature neonates. Pharmacotherapy 1991;11:269–70.


  70. Fasano C, OTCeeffe J, Gibbs D. Fluconazole treatment of neo-nates and infants with severe fungal infections not treatable with conventional agents. Eur J Clin Microbiol Infect Dis 1994; 13(4):351–54.


  71. Bilgen H, Ozek E, Korten V, et al. Treatment of systemic neonatal candidiasis with fluconazole [letter]. Infection 1995;23(6):394.


  72. Narang A, Agrawal P, Chakraborti A, et al. Fluconazole in the management of neonatal systemic candidiasis. Indian Pediatr 1996;33(10):823–26.


  73. Wainer S, Cooper PA, Gouws H, et al. Prospective study of fluconazole therapy in systemic neonatal fungal infection. Pediatr Infect Dis J 1997;16(8):763–67.


  74. Driessen M, Ellis JB, Muwazi F, et al. The treatment of systemic candidiasis in neonates with oral fluconazole. Ann Trop Paediatr 1997;17(3):263–71.


  75. Huttova M, Hartmanova I, Kralinsky K, et al. Candida fungemia in neonates treated with fluconazole: report of forty cases, including eight with meningitis. Pediatr Infect Dis J 1998;17(11): 1012–15.


  76. Merchant RH, Sanghvi KP, Sridhar N, et al. Nursery outbreak of neonatal fungal arthritis treated with fluconazole. J Trop Pediatr 1997;43(2): 106–08.


  77. Oleinik EM, Della-Latta P, Rinaldi MG, et al. Candida lusitaniae osteomyelitis in a premature infant. Am J Perinatol 1993;10(4):313–15.


  78. Kaufman D, Boyle R, Hazen KC, et al. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med 2001;345(23):1660–66.


  79. Алексеева В.В., Буслаева Г.Н., Самсыгина Г.А. Нейпоген в терапии тяжелых инфекционных заболеваний у детей. Тезисы V Российского Национального конгресса “Человек и лекарство”. Москва, 1998, 250.


  80. Самсыгина Г.А., Буслаева Г.Н. Кандидоз новорожденных и детей первого года жизни (пособие для практических врачей). М., 2004, 64 с.


  81. Bennett JE. Antifungal agents. In: Hardman GE, Limbird LE, editors. Goodman and Oilman's the pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill 2001, р. 1295–312.


  82. Raasch RH, Hopfer RL. Antifungal agents. In: Munson PL, editor. Principles of pharmacology: basic concepts and clinical applications, revised reprint. New York: Chapman and Hall 1995, р. 1401–11.


  83. Tollins JP, Raij L. Adverse effects of amphotericin B adminis-tration on renal hemodynamics in the rat: neurohumoral mechanisms and influence of calcium channel blockade. J Pharmacol Exp Ther 1998;245:594–99.


  84. Steinmetz PR, Hustead RF. Amphotericin B toxicity of epi-thelial cells. In: Porter GA, editor. Nephrotoxic mechanisms of drugs and environmental toxins. New York (NY): Kluwer Academic/Plenum Publishers 1982, р. 9S–8.


  85. Ramos KS, Chacon E, Acosta D. Toxic responses of the heart and vascular systems. In: Klassen CD, editor. Casarett and Doul's toxicology: the basic science of poisons. 5th ed. New York: McGraw-Hill 1996, р. 498–501.


  86. Frattarelli DAC, Reed MD, Giacoia GP, et al. Antifungals in Systemic Neonatal Candidiasis. Drugs 2004;64(9):949–98.





Бионика Медиа